Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Methodological detailsmultidisciplinary taskforce, informed by two systematic literature reviews, EULAR standard operating procedures, voting
- Multidisciplinary taskforce
- Informed by two systematic literature reviews
- EULAR standard operating procedures
- Voting
Scope
As issued by the authors
Use of Janus kinase inhibitors (JAKi) in IMID: overarching principles, indications, dosage and comedication strategies, warnings and contraindications, screening, monitoring and adverse effect profiles; not when a JAKi should be prescribed, but considerations once this decision has been made
Original publication
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update. Ann Rheum Dis. Published 3 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →